Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the
discovery testing and development of epigenetic cancer drugs. Epigenetic modifications can
have significant implications for translational science as biomarkers for diagnosis prognosis
or therapy prediction. Most importantly epigenetic modifications are reversible and epigenetic
players are found mutated in different cancers therefore they provide attractive therapeutic
targets. There has been great interest in developing and testing epigenetic drugs which
inhibit DNA methyltransferases histone modifying enzymes or chromatin reader proteins. The
first few drugs are already FDA approved and have made their way into clinical settings. This
book provides a comprehensive summary of the epigenetic drugs currently available and aims to
increase awareness in this area to foster more rapid translation of epigenetic drugs into the
clinic.
